SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-028846
Filing Date
2023-08-10
Accepted
2023-08-10 16:08:49
Documents
12
Period of Report
2023-08-09
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20230809.htm   iXBRL 8-K 30240
  Complete submission text file 0001628280-23-028846.txt   159412

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20230809.xsd EX-101.SCH 1907
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20230809_lab.xml EX-101.LAB 24846
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20230809_pre.xml EX-101.PRE 13047
6 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20230809_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 231159384
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences